Inflammation and cancer
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index; 8 of the 94 sources its claims cite were checked for support.
Abstract
Recent data have expanded the concept that inflammation is a critical component of tumour progression. Many cancers arise from sites of infection, chronic irritation and inflammation. It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration. In addition, tumour cells have co-opted some of the signalling molecules of the innate immune system, such as selectins, chemokines and their receptors for invasion, migration and metastasis. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.
Overview
CoChat Summary
TL;DR
This review argues that inflammation is a critical component of tumour progression, with inflammatory cells and their mediators fostering proliferation, survival, angiogenesis, invasion and metastasis. It synthesizes evidence linking chronic infection/inflammation to cancer and discusses anti-inflammatory therapeutic opportunities.
Key findings
- Many cancers arise from sites of infection, chronic irritation and inflammation; the tumour microenvironment, largely orchestrated by inflammatory cells, is an indispensable participant in neoplasia, fostering proliferation, survival and migration.
- Upwards of 15% of malignancies worldwide are attributable to infections, a global total of 1.2 million cases per year; chronic inflammatory conditions are associated with neoplasms including colorectal carcinoma in inflammatory bowel disease and gastric cancer with chronic *Helicobacter pylori* infection, the second most common cancer globally.
- In MMTV-PyMT mammary cancer mice crossed with CSF-1-null (*Csf1op*) mice, absence of CSF-1 had no apparent early consequence, but late-stage invasive carcinoma and pulmonary metastases were significantly attenuated; targeting CSF-1 to mammary epithelium restored macrophage recruitment, primary tumour development and metastatic potential.
- Long-term aspirin/NSAID use reduces colon cancer risk by 40–50% and may be preventative for lung, oesophagus and stomach cancer; tumour cells also co-opt innate immune signalling molecules such as selectins, chemokines and their receptors for invasion, migration and metastasis.
Methods
- Narrative review; no primary experiments or new patient/animal data are reported.
- Synthesizes published literature on inflammation, innate immunity, wound healing, inflammatory cell types, chemokines, chronic inflammation-associated cancers, selectin/MMP biology and anti-inflammatory therapy.
- Main analysis is conceptual synthesis and interpretation of cited studies; no systematic search strategy, inclusion criteria or quantitative meta-analysis is described.
Limitations
- The paper states that the acquired immune response to cancer is intimately related to the inflammatory response but is beyond the scope of the article.
- Evident from the text: as a narrative review, it lacks a systematic search or formal evidence appraisal, and conclusions depend on the cited studies.
- Evident from the text: many molecular and cellular mechanisms mediating the inflammation–cancer relationship remain unresolved, and therapeutic implications are largely based on observational, animal or preclinical evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 1 Not valid · 66 Not checked · 35 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition to altering the local balance of pro-angiogenic factors during melanoma development, during human cervical carcinogenesis, TAMs express VEGF-C and VEGF-D as well as the VEGF receptor-3 (VEGFR-3), all of which are implicated in formation of lymphatic vessels and lymphatic metastases17.”
What the sources say
- Supportedcites [17] Schoppmann S, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161:947–956. doi: 10.1016/S0002-9440(10)64255-1. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Abstract (p.1) states that in human cervical cancers the VEGF-C- and VEGF-D-producing stromal cells were identified in situ as a subset of activated TAMs (CD68, CD23, CD14) that 'also expressed the VEGF-C-and VEGF-D-specific tyrosine kinase receptor VEGFR-3'. The Discussion reinforces this: 'All VEGF-C-and VEGF-D-producing TAMs co-expressed also the corresponding tyrosine kinase receptor VEGFR-3', and links their density to peritumoral lymphatic microvessel density, lymphangiosis carcinomatosa and lymph-node metastasis, i.e. lymphatic vessel formation and lymphatic spread. The melanoma clause of the citing sentence belongs to a different citation and was not judged here. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Tumour cells produce various cytokines and chemokines that attract leukocytes.”
What the sources say
- Could not verifycites [11] Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171–183. doi: 10.1046/j.1365-2796.2000.00742.x. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Helicobacter pylori section (p. 9) describes white blood cells being attracted during inflammation, followed by increased cytokine production. The Mechanisms section (p. 2) discusses inflammation caused by infection. Neither passage says that tumour cells produce cytokines or chemokines to attract leukocytes; searches for those terms found no supporting passage. (LLM, conf=0.76)
- Partly supportedcites [12] Wahl LM, Kleinman HK. Tumor-associated macrophages as targets for cancer therapy. J Natl Cancer Inst. 1998;90:1583–1584. doi: 10.1093/jnci/90.21.1583. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
On p. 1, the paper says tumor-derived attractants, including monocyte chemotactic protein-1, recruit tumor-associated macrophages to tumors. It also lists several tumor-derived cytokines, but describes them as reducing macrophage cytotoxicity, not attracting leukocytes. The claim extends the recruitment point beyond the macrophages and attractant discussed in the paper. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The key difference between PyMT mice and PyMT/Csf1op/Csf1op mice is not in the apparent proliferative capacity of neoplastic epithelial cells, but in the failure to recruit mature macrophages into neoplastic tissue in the absence of CSF-1.”
What the sources say
- Supportedcites [21] Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727–740. doi: 10.1084/jem.193.6.727. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Introduction reports that CSF-1 deficiency did not affect primary mammary tumor growth but delayed macrophage recruitment. The Results section (“Absence of CSF-1 Does Not Effect Growth of the Primary Mammary Tumor”) found no significant difference in tumor-cell proliferation, and the Discussion reports no macrophage infiltration at the tumor site in CSF-1-null PyMT mice. Page numbers are not provided in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Genetic and functional experiments indicate that neutrophils, mast cells, eosinophils and activated T lymphocytes also contribute to malignancies by releasing extracellular proteases, pro-angiogenic factors and chemokines11,23–26.”
What the sources say
- Partly supportedcites [11] Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171–183. doi: 10.1046/j.1365-2796.2000.00742.x. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Mechanisms section (p. 2) says inflammatory phagocytes produce reactive oxygen and nitrogen species that can favor carcinogenesis. The H. pylori section (p. 9) links recruited white blood cells and cytokines to oxidative DNA damage. Neither passage establishes the claimed contribution of all four named cell types through extracellular proteases, pro-angiogenic factors, and chemokines, or cites genetic and functional experiments for it. (LLM, conf=0.78)
- Not checked yetcites [23] DiCarlo E, et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood. 2001;97:339–345. doi: 10.1182/blood.v97.2.339. [DOI] [PubMed] [Google Scholar] source
- Partly supportedcites [24] Coussens LM, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999;13:1382–1397. doi: 10.1101/gad.13.11.1382. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Conclusion (page unavailable) links mast cells to angiogenesis during premalignant squamous carcinogenesis through the release of pro-angiogenic proteases. The paper does not establish the claimed roles of neutrophils, eosinophils or activated T lymphocytes, or their release of chemokines. (LLM, conf=0.86)
- Not checked yetcites [25] Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–490. doi: 10.1016/s0092-8674(00)00139-2. [DOI] [PMC free article] [PubMed] [Google Scholar] source
- Partly supportedcites [26] Bergers G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2000;2:737–744. doi: 10.1038/35036374. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies mast cells and neutrophils as suppliers of MMP-9 in a model of squamous carcinogenesis, and reports that MMP-9 can mobilize VEGF during angiogenesis. Our copy does not establish the claimed roles for eosinophils or activated T lymphocytes, or say that these cells contribute by releasing chemokines. (LLM, conf=0.87)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
In the paper
“Indeed, macrophage infiltration is closely associated with the depth of invasion of primary melanoma due, in part, to macrophage-regulated tumour-associated angiogenesis19.”
What the sources say
- Not checked yetcites [19] Ono M, Torisu H, Fukushi J, Nishie A, Kuwano M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol. 1999;43:S69–S71. doi: 10.1007/s002800051101. [DOI] [PubMed] [Google Scholar] source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
76 more claims
Create a free account to see all 107 claims and to verify the 86 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic inflammation is also important for carcinogenesis, as pro-inflammatory cytokines, including IL-1β, can be tumour promoting6,111.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many of these processes also occur in cancer as most of them are inflammation-related, including hypoxia-induced neovascularization, endothelial dysfunction, permeability of the microvasculature and the upregulation of adhesion molecules to facilitate the recruitment of cells30,31.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inflammatory cells such as macrophages and neutrophils can cause immunosuppression in the TME.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides promoting cell proliferation, the action of cytokines in promoting cancer development includes antagonizing anti-tumor immune response, recruiting tumor-supportive stromal cells and immune-suppressive cells, inducing angiogenesis and metastasis, and altering the responses to therapeutic agents (10, 15)”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, rather than the dogma that oncogenesis is intrinsically triggered in pre-neoplastic cells, environmental factors, such as infection, stress, obesity, aging and smoking, each of which can induce chronic inflammation, could be a major cause of oncogenesis (4, 6, 9, 233).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Self-citationMatrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Self-citationThe Biology of Chemokines and their Receptors
Rossi, D., & Zlotnik, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.217 · Cited by 2,410 · cited 1×
“A family of chemotactic cytokines, named chemokines, which possess a relatively high degree of specificity for chemoattraction of specific leukocyte population”
Cited by
Items 501–600 of 1,179
Vasiljeva, O., Papazoglou, A., Krüger, A., Brodoefel, H., Korovin, M., Deussing, J., Augustin, N., Nielsen, B. S., Almholt, K., Bogyo, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4463 · Cited by 375
Singh, S., Sharma, A. N., Murad, M. H., Buttar, N. S., El–Serag, H. B., Katzka, D. A., & Iyer, P. G. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.05.009 · Cited by 381
Bower, J. E., & Lamkin, D. M. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.06.011 · Cited by 372
Tumor-Associated Macrophages: The Double-Edged Sword in Cancer Progression
Chen, J. J. W., Lin, Y.-C., Yao, P.-L., Yuan, A., Chen, H.-Y., Shun, C.-T., Tsai, M.-F., Chen, C.-H., & Yang, P.-C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.172 · Cited by 374
Hypoxia, inflammation, and the tumor microenvironment in metastatic disease
Finger, E. C., & Giaccia, A. J. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9224-5 · Cited by 370
Excisional surgery for cancer cure: therapy at a cost
Coffey, J., Wang, J., Smith, M., Bouchier-Hayes, D., Cotter, T., & Redmond, H. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01282-8 · Cited by 374
Hagemann, T. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh146 · Cited by 375
Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease
Pavlick, K. P., Laroux, F. S., Fuseler, J., Wolf, R. E., Gray, L., Hoffman, J., & Grisham, M. B. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00853-5 · Cited by 373
Immune cells as mediators of solid tumor metastasis
DeNardo, D. G., Johansson, M., & Coussens, L. M. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9100-0 · Cited by 372
Self-citationBremnes, R. M., Al-Shibli, K., Donnem, T., Sirera, R., Al-Saad, S., Andersen, S., Stenvold, H., Camps, C., & Busund, L.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182037b76 · Cited by 369
Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment
Hoelzinger, D. B., Demuth, T., & Berens, M. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm187 · Cited by 372
Nowell, C. S., & Radtke, F. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.145 · Cited by 369
Cellular Constituents of Immune Escape within the Tumor Microenvironment
Kerkar, S. P., & Restifo, N. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4094 · Cited by 370
Almatroodi, S. A., Almatroudi, A., Khan, A. A., Alhumaydhi, F. A., Alsahli, M. A., & Rahmani, A. H. (2020) · Molecules · doi:10.3390/molecules25143146 · Cited by 365
Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice
Sawanobori, Y., Ueha, S., Kurachi, M., Shimaoka, T., Talmadge, J. E., Abe, J., Shono, Y., Kitabatake, M., Kakimi, K., Mukaida, N., et al. (2008) · Blood · doi:10.1182/blood-2008-01-136895 · Cited by 367
Inflammatory pathways in female reproductive health and disease
Jabbour, H. N., Sales, K. J., Catalano, R. D., & Norman, J. E. (2009) · Reproduction · doi:10.1530/rep-09-0247 · Cited by 367
The metastasis-promoting roles of tumor-associated immune cells
Smith, H. A., & Kang, Y. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1021-5 · Cited by 367
Accioly, M. T., Pacheco, P., Maya-Monteiro, C. M., Carrossini, N., Robbs, B. K., Oliveira, S. S., Kaufmann, C., Morgado-Diaz, J. A., Bozza, P. T., & Viola, J. P. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1999 · Cited by 365
Tumour necrosis factor-α as a tumour promoter
Szlosarek, P., Charles, K. A., & Balkwill, F. R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.012 · Cited by 366
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice
Lu, T., Ramakrishnan, R., Altiok, S., Youn, J.-I., Cheng, P., Celis, E., Pisarev, V., Sherman, S., Sporn, M. B., & Gabrilovich, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45862 · Cited by 367
Targeting Inflammation in Cancer Prevention and Therapy
Todoric, J., Antonucci, L., & Karin, M. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0209 · Cited by 354
Liu, J., Li, S., Zhang, S., Liu, Y., Ma, L., Zhu, J., Xin, Y., Wang, Y., Yang, C., & Cheng, Y. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22964 · Cited by 364
Ren, G., Zhao, X., Wang, Y., Zhang, X., Chen, X., Xu, C., Yuan, Z.-R., Roberts, A. I., Zhang, L., Zheng, B., et al. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.08.013 · Cited by 361
Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis
Canli, Ö., Nicolas, A. M., Gupta, J., Finkelmeier, F., Goncharova, O., Pesic, M., Neumann, T., Horst, D., Löwer, M., Sahin, U., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.004 · Cited by 359
Multi-targeted therapy of cancer by omega-3 fatty acids
Berquin, I. M., Edwards, I. J., & Chen, Y. Q. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.044 · Cited by 364
Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone Marrow
Yang, F.-C., Ingram, D. A., Chen, S., Zhu, Y., Yuan, J., Li, X., Yang, X., Knowles, S., Horn, W., Li, Y., et al. (2008) · Cell · doi:10.1016/j.cell.2008.08.041 · Cited by 364
Vaccari, T., & Bilder, D. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.09.019 · Cited by 363
Surh, Y.-J., Kundu, J. K., Na, H.-K., & Lee, J.-S. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.12.2993s · Cited by 363
Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.
Quatromoni, J. G., & Eruslanov, E. B. (2012) · Europe PMC (PubMed Central) · Cited by 458
Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells
Dadi, S., Chhangawala, S., Whitlock, B. M., Franklin, R. A., Luo, C. T., Oh, S. A., Toure, A., Pritykin, Y., Huse, M., Leslie, C. S., et al. (2016) · Cell · doi:10.1016/j.cell.2016.01.002 · Cited by 359
Recent progress in the development of fluorescent probes for imaging pathological oxidative stress
Geng, Y., Wang, Z., Zhou, J., Zhu, M., Liu, J., & James, T. D. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00172a · Cited by 351
Germolec, D. R., Shipkowski, K. A., Frawley, R. P., & Evans, E. (2018) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8549-4_5 · Cited by 346
Post-prenylation-processing enzymes as new targets in oncogenesis
Winter-Vann, A. M., & Casey, P. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1612 · Cited by 357
Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis
Corliss, B. A., Azimi, M. S., Munson, J. M., Peirce, S. M., & Murfee, W. L. (2016) · Microcirculation · doi:10.1111/micc.12259 · Cited by 356
The integration of inflammaging in age-related diseases
Fulop, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.003 · Cited by 348
The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies
Sobolewski, C., Cerella, C., Dicato, M., Ghibelli, L., & Diederich, M. (2010) · International Journal of Cell Biology · doi:10.1155/2010/215158 · Cited by 354
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia
Klein, G., Vellenga, E., Fraaije, M. W., Kamps, W. A., & de Bont, E. S. J. M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.001 · Cited by 350
The proliferation rate paradox in antimitotic chemotherapy
Mitchison, T. J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-04-0335 · Cited by 363
Human cancers express a mutator phenotype
Bielas, J. H., Loeb, K. R., Rubin, B. P., True, L. D., & Loeb, L. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607057103 · Cited by 354
Benoy, I. H., Salgado, R., Van Dam, P., Geboers, K., Van Marck, E., Scharpé, S., Vermeulen, P. B., & Dirix, L. Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0812 · Cited by 356
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Zhou, J., Mahoney, K. M., Giobbie-Hurder, A., Zhao, F., Lee, S., Liao, X., Rodig, S., Li, J., Wu, X., Butterfield, L. H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0329 · Cited by 352
Strategies for the discovery and development of therapies for metastatic breast cancer
Eckhardt, B. L., Francis, P. A., Parker, B. S., & Anderson, R. L. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2372 · Cited by 349
A review of the relationship between tooth loss, periodontal disease, and cancer
Meyer, M. S., Joshipura, K., Giovannucci, E., & Michaud, D. S. (2008) · Cancer Causes & Control · doi:10.1007/s10552-008-9163-4 · Cited by 349
Siemes, C., Visser, L. E., Coebergh, J.-W. W., Splinter, T. A. W., Witteman, J. C. M., Uitterlinden, A. G., Hofman, A., Pols, H. A. P., & Stricker, B. H. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1381 · Cited by 354
CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer
Kiniwa, Y., Miyahara, Y., Wang, H. Y., Peng, W., Peng, G., Wheeler, T. M., Thompson, T. C., Old, L. J., & Wang, R.-F. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0842 · Cited by 352
Tumor-associated macrophages: Effectors of angiogenesis and tumor progression
Coffelt, S. B., Hughes, R., & Lewis, C. E. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.02.004 · Cited by 355
Inflammation and oxidative stress in vertebrate host–parasite systems
Sorci, G., & Faivre, B. (2009) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0151 · Cited by 347
Paracrine and Endocrine Effects of Adipose Tissue on Cancer Development and Progression
Park, J., Euhus, D. M., & Scherer, P. E. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0030 · Cited by 348
Adrover, J. M., McDowell, S. A. C., He, X.-Y., Quail, D. F., & Egeblad, M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.001 · Cited by 338
Huang, B., Lei, Z., Zhang, G.-M., Li, D., Song, C., Li, B., Liu, Y., Yuan, Y., Unkeless, J., Xiong, H., et al. (2008) · Blood · doi:10.1182/blood-2008-03-147033 · Cited by 345
Herb and Spices in Colorectal Cancer Prevention and Treatment: A Narrative Review
Hossain, M. S., Kader, M. A., Goh, K. W., Islam, M., Khan, M. S., Harun-Ar Rashid, M., Ooi, D. J., Melo Coutinho, H. D., Al-Worafi, Y. M., Moshawih, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.865801 · Cited by 346
Role of macrophages in tumour progression
Siveen, K. S., & Kuttan, G. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.02.011 · Cited by 353
Association of the Vaginal Microbiota with Human Papillomavirus Infection in a Korean Twin Cohort
Lee, J. E., Lee, S., Lee, H., Song, Y.-M., Lee, K., Han, M. J., Sung, J., & Ko, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063514 · Cited by 340
S100A8/A9 activate key genes and pathways in colon tumor progression
Ichikawa, M., Williams, R., Wang, L., Vogl, T., & Srikrishna, G. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0394 · Cited by 346
Previous Lung Diseases and Lung Cancer Risk: A Systematic Review and Meta-Analysis
Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017479 · Cited by 343
Macarthur, M., Hold, G. L., & El-Omar, E. M. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00475.2003 · Cited by 348
Mantovani, A., Sica, A., Allavena, P., Garlanda, C., & Locati, M. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.02.008 · Cited by 350
Ono, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00853.x · Cited by 342
Law, W. L., Choi, H. K., Lee, Y. M., Ho, J. W. C., & Seto, C. L. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-006-0049-z · Cited by 346
Pushalkar, S., Ji, X., Li, Y., Estilo, C., Yegnanarayana, R., Singh, B., Li, X., & Saxena, D. (2012) · BMC Microbiology · doi:10.1186/1471-2180-12-144 · Cited by 339
Teramukai, S., Kitano, T., Kishida, Y., Kawahara, M., Kubota, K., Komuta, K., Minato, K., Mio, T., Fujita, Y., Yonei, T., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.01.023 · Cited by 344
Kartikasari, A. E. R., Huertas, C. S., Mitchell, A., & Plebanski, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692142 · Cited by 343
“Besides promoting cell proliferation, the action of cytokines in promoting cancer development includes antagonizing antitumor immune response, recruiting tumor-supportive stromal cells and immune-suppressive cells, inducing angiogenesis and metastasis, and altering the responses to therapeutic agents (10, 15) (Figure…”
BackgroundWang, K., Kim, M. K., Di Caro, G., Wong, J., Shalapour, S., Wan, J., Zhang, W., Zhong, Z., Sanchez-Lopez, E., Wu, L.-W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.11.009 · Cited by 341
Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?
Micke, P., & tman, A. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.07.977 · Cited by 344
Fibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT?
Radisky, D. C., Kenny, P. A., & Bissell, M. J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21186 · Cited by 344
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342
Oxidative stress promotes myofibroblast differentiation and tumour spreading
Toullec, A., Gerald, D., Despouy, G., Bourachot, B., Cardon, M., Lefort, S., Richardson, M., Rigaill, G., Parrini, M., Lucchesi, C., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000073 · Cited by 339
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
He, W., Liu, Q., Wang, L., Chen, W., Li, N., & Cao, X. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.01.022 · Cited by 340
Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots
Korkaya, H., Liu, S., & Wicha, M. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2743 · Cited by 334
Immune suppression and immune activation in depression
Blume, J., Douglas, S. D., & Evans, D. L. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.008 · Cited by 338
Inflammation and the development of pancreatic cancer
Farrow, B., & Evers, B. M. (2002) · Surgical Oncology · doi:10.1016/s0960-7404(02)00015-4 · Cited by 338
Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond
Kaplan, R. N., Psaila, B., & Lyden, D. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9036-9 · Cited by 336
Anti-Inflammatory Agents for Cancer Therapy
Rayburn, E. (2009) · Molecular and Cellular Pharmacology · doi:10.4255/mcpharmacol.09.05 · Cited by 341
Oral lichen planus: controversies surrounding malignant transformation
Gonzalez‐Moles, M., Scully, C., & Gil‐Montoya, J. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2008.01441.x · Cited by 334
Nath, A., Li, I., Roberts, L. R., & Chan, C. (2015) · Scientific Reports · doi:10.1038/srep14752 · Cited by 338
Dewson, G., Eichhorn, P. J. A., & Komander, D. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00633-y · Cited by 326
Aspord, C., Pedroza-Gonzalez, A., Gallegos, M., Tindle, S., Burton, E. C., Su, D., Marches, F., Banchereau, J., & Palucka, A. K. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061120 · Cited by 334
Bhatti, I., Peacock, O., Lloyd, G., Larvin, M., & Hall, R. I. (2010) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2009.08.041 · Cited by 333
Macrophage Polarization in Health and Disease
Cassetta, L., Cassol, E., & Poli, G. (2011) · The Scientific World JOURNAL · doi:10.1100/2011/213962 · Cited by 330
Metabolic Reprogramming of Cancer-Associated Fibroblasts by IDH3α Downregulation
Zhang, D., Wang, Y., Shi, Z., Liu, J., Sun, P., Hou, X., Zhang, J., Zhao, S., Zhou, B. P., & Mi, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.006 · Cited by 333
Th17 Cells in Cancer: The Ultimate Identity Crisis
Bailey, S. R., Nelson, M. H., Himes, R. A., Li, Z., Mehrotra, S., & Paulos, C. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00276 · Cited by 334
The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion
Mojic, M., Takeda, K., & Hayakawa, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010089 · Cited by 334
Biology, vulnerabilities and clinical applications of circulating tumour cells
Ring, A., Nguyen-Sträuli, B. D., Wicki, A., & Aceto, N. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00536-4 · Cited by 327
Chapter 8 The Role of NKT Cells in Tumor Immunity
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00408-9 · Cited by 316
BENBARUCH, A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.006 · Cited by 335
Biology of Platelet-Derived Growth Factor and Its Involvement in Disease
Alvarez, R. H., Kantarjian, H. M., & Cortes, J. E. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.9.1241 · Cited by 334
Kang, R., Tang, D., Schapiro, N. E., Livesey, K. M., Farkas, A., Loughran, P., Bierhaus, A., Lotze, M. T., & Zeh, H. J. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.149 · Cited by 283
Lindsay, M. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1202 · Cited by 332
He, X., Li, Y., Deng, B., Lin, A., Zhang, G., Ma, M., Wang, Y., Yang, Y., & Kang, X. (2022) · Cell Proliferation · doi:10.1111/cpr.13275 · Cited by 326
Cardiovascular Disease Risk Among Cancer Survivors
Florido, R., Daya, N. R., Ndumele, C. E., Koton, S., Russell, S. D., Prizment, A., Blumenthal, R. S., Matsushita, K., Mok, Y., Felix, A. S., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.04.042 · Cited by 319
The Role of Macrophages in Cancer Development and Therapy
Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P. (2021) · Cancers · doi:10.3390/cancers13081946 · Cited by 332
“TGFβ is also produced by activated macrophages and plays a dual, pro-, or anti-inflammatory role [31,32].”
BackgroundRole of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
Shojaei, F., Singh, M., Thompson, J. D., & Ferrara, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712185105 · Cited by 334
Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis
Bard-Chapeau, E. A., Li, S., Ding, J., Zhang, S. S., Zhu, H. H., Princen, F., Fang, D. D., Han, T., Bailly-Maitre, B., Poli, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.023 · Cited by 332
Transforming growth factor beta (TGF-β) and inflammation in cancer
Bierie, B., & Moses, H. L. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.008 · Cited by 334
Ladoire, S., Martin, F., & Ghiringhelli, F. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1046-y · Cited by 331
The reactive stroma microenvironment and prostate cancer progression
Barron, D. A., & Rowley, D. R. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0085 · Cited by 329
Pine, S. R., Mechanic, L. E., Enewold, L., Chaturvedi, A. K., Katki, H. A., Zheng, Y.-L., Bowman, E. D., Engels, E. A., Caporaso, N. E., & Harris, C. C. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr216 · Cited by 333
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene
Borrello, M. G., Alberti, L., Fischer, A., Degl'Innocenti, D., Ferrario, C., Gariboldi, M., Marchesi, F., Allavena, P., Greco, A., Collini, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503039102 · Cited by 331
Hyperglycemia as a Risk Factor for Cancer Progression
Ryu, T. Y., Park, J., & Scherer, P. E. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.5.330 · Cited by 331
Metadata
- Authors
- Coussens, L. M., & Werb, Z.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Nature
- Published
- 2002-12
- Volume
- 420
- Issue
- 6917
- Pages
- 860-867
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2803035
- OpenAlex
- W1965037168
- Cited by
- 15,111
- References
- 88
- Citations by year
- 2026: 328 · 2025: 590 · 2024: 701 · 2023: 849 · 2022: 873 · 2021: 934 · 2020: 858 · 2019: 827 · 2018: 742 · 2017: 775 · 2016: 756 · 2015: 773 · 2014: 776 · 2013: 749 · 2012: 689
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- V Foundation for Cancer Research
- Edward Mallinckrodt, Jr. Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health
- National Cancer Institute (P01CA072006, R01CA057621)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Keywords
- inflammation, cancer, tumor microenvironment, tumor progression, chronic inflammation, infection-associated cancer, inflammatory cells, tumor cell proliferation, cell migration, metastasis, innate immune signaling, selectins, chemokines, chemokine receptors
- MeSH terms
- Animals, Chronic Disease, Humans, Inflammation, Leukocytes, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Disease Progression, Chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.